Therapeutic Drug Monitoring of Voriconazole in Children

Voriconazole is an extended-spectrum triazole antifungal with activity against a wide variety of pathogens, including Aspergillus, Candida, Cryptococcus neoformans, Fusarium, and Scedosporium. It exerts its antifungal activity by blocking the synthesis of fungal cell membranes and is considered the first-line treatment for invasive aspergillosis. Because the pharmacokinetics of voriconazole can demonstrate considerable variability, it has been suggested that monitoring plasma levels of voriconazole may play an important role in optimizing the efficacy and safety of the drug in complex patients like those at risk of or who have invasive aspergillosis. In this article, we review the criteria for therapeutic drug monitoring and assess the evidence for using plasma voriconazole concentrations to individualize doses in children.

[1]  A. Warris,et al.  Impact of Therapeutic Drug Monitoring of Voriconazole in a Pediatric Population , 2011, The Pediatric infectious disease journal.

[2]  W. Haefeli,et al.  Modulators of Very Low Voriconazole Concentrations in Routine Therapeutic Drug Monitoring , 2011, Therapeutic drug monitoring.

[3]  R. Guillemain,et al.  Pharmacological considerations for azole antifungal drug management in cystic fibrosis lung transplant patients. , 2010, Medical mycology.

[4]  S. Goutelle,et al.  Oral voriconazole dose in children: one size does not fit all. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  S. Eymard-Duvernay,et al.  Pharmacokinetic variability of voriconazole and N-oxide voriconazole measured as therapeutic drug monitoring , 2010, Xenobiotica; the fate of foreign compounds in biological systems.

[6]  D. Marriott,et al.  Voriconazole concentrations and outcome of invasive fungal infections. , 2010, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[7]  H. Shimada,et al.  Differences in voriconazole trough plasma concentrations per oral dosages between children younger and older than 3 years of age , 2010, Pediatric blood & cancer.

[8]  D. Niederwieser,et al.  Voriconazole Pharmacokinetics and Safety in Immunocompromised Children Compared to Adult Patients , 2010, Antimicrobial Agents and Chemotherapy.

[9]  T. Patterson,et al.  Voriconazole use and pharmacokinetics in combination with interferon-gamma for refractory cryptococcal meningitis in a patient receiving low-dose ritonavir. , 2010, Medical mycology.

[10]  M. Xavier,et al.  Voriconazole therapeutic drug monitoring: focus on safety , 2010, Expert opinion on drug safety.

[11]  J. Ibrahim,et al.  In Vitro Hepatic Metabolism Explains Higher Clearance of Voriconazole in Children versus Adults: Role of CYP2C19 and Flavin-Containing Monooxygenase 3 , 2010, Drug Metabolism and Disposition.

[12]  R. Jelliffe,et al.  Voriconazole pharmacokinetics and pharmacodynamics in children. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  H. Derendorf,et al.  Pharmacokinetic/Pharmacodynamic Profile of Posaconazole , 2010, Clinical pharmacokinetics.

[14]  M. Loriot,et al.  Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients , 2009, Transplant infectious disease : an official journal of the Transplantation Society.

[15]  M. Kurokawa,et al.  Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders , 2009, International journal of hematology.

[16]  P. Annaert,et al.  Pharmacokinetics of caspofungin and voriconazole in critically ill patients during extracorporeal membrane oxygenation. , 2009, The Journal of antimicrobial chemotherapy.

[17]  J. Sobel,et al.  Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  Mats O. Karlsson,et al.  Population Pharmacokinetic Analysis of Voriconazole Plasma Concentration Data from Pediatric Studies , 2008, Antimicrobial Agents and Chemotherapy.

[19]  P. Hoogerbrugge,et al.  Therapeutic drug monitoring of voriconazole in a child with invasive aspergillosis requiring extracorporeal membrane oxygenation. , 2008, Therapeutic drug monitoring.

[20]  D. Touw,et al.  International Interlaboratory Proficiency Testing Program for Measurement of Azole Antifungal Plasma Concentrations , 2008, Antimicrobial Agents and Chemotherapy.

[21]  A. Pakyz,et al.  Adverse drug events complicate antifungal therapy for pulmonary aspergilloma. , 2008, The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists.

[22]  J. Donnelly,et al.  Therapeutic Drug Monitoring of Voriconazole , 2008, Therapeutic drug monitoring.

[23]  J. Gea-Banacloche,et al.  Hallucinations during voriconazole therapy. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  R. Preiss,et al.  Determination of voriconazole in human plasma and saliva using high-performance liquid chromatography with fluorescence detection. , 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[25]  W. Peetermans,et al.  Aggressive Cutaneous Squamous Cell Carcinoma Associated with Prolonged Voriconazole Therapy in a Renal Transplant Patient , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[26]  Hikaru Kobayashi,et al.  Determination of the antifungal agent voriconazole in human plasma using a simple column-switching high-performance liquid chromatography and its application to a pharmacokinetic study. , 2008, Chemical & pharmaceutical bulletin.

[27]  D. Denning,et al.  Voriconazole plasma monitoring , 2008, Archives of Disease in Childhood.

[28]  Raoul Herbrecht,et al.  Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  R. Lewis What is the "therapeutic range" for voriconazole? , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30]  Thierry Buclin,et al.  Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  A. Dasgupta Introduction to Therapeutic Drug Monitoring , 2008 .

[32]  J. Kosterink,et al.  High-dose voriconazole in a critically ill pediatric patient with neuroblastoma. , 2008, The Pediatric Infectious Disease Journal.

[33]  F. Boakye-Agyeman,et al.  Measurement of voriconazole in serum and plasma. , 2007, Clinical biochemistry.

[34]  D. Kontoyiannis,et al.  Random plasma concentrations of voriconazole decline over time. , 2007, The Journal of infection.

[35]  W. Vogel,et al.  Altered Pharmacokinetics of Voriconazole in a Patient with Liver Cirrhosis , 2007, Antimicrobial Agents and Chemotherapy.

[36]  D. Hillaire‐buys,et al.  Adverse Effects of Voriconazole: Analysis of the French Pharmacovigilance Database , 2007, The Annals of pharmacotherapy.

[37]  A. Mejias,et al.  Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, voriconazole and micafungin. , 2007, The Pediatric infectious disease journal.

[38]  J. Mehta,et al.  Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy , 2007, Bone Marrow Transplantation.

[39]  E. Jerome Compendium of pharmaceuticals and specialties : the Canadian drug reference for health professionals , 2007 .

[40]  K. Sepkowitz,et al.  Issues related to the design and interpretation of clinical trials of salvage therapy for invasive mold infection. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[41]  D. Schaer,et al.  Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. , 2006, Swiss medical weekly.

[42]  T. Buclin,et al.  Variability of Voriconazole Plasma Levels Measured by New High-Performance Liquid Chromatography and Bioassay Methods , 2006, Antimicrobial Agents and Chemotherapy.

[43]  W. Haefeli,et al.  Voriconazole Concentration in Human Aqueous Humor and Plasma during Topical or Combined Topical and Systemic Administration for Fungal Keratitis , 2006, Antimicrobial Agents and Chemotherapy.

[44]  Lauren A. Destino,et al.  Annals of Clinical Microbiology and Antimicrobials Open Access Severe Osteomyelitis Caused by Myceliophthora Thermophila after a Pitchfork Injury , 2022 .

[45]  J. Kuchta,et al.  Voriconazole brain tissue levels in rhinocerebral aspergillosis in a successfully treated young woman. , 2006, International journal of antimicrobial agents.

[46]  D. Andes,et al.  Pharmacology of Systemic Antifungal Agents , 2006 .

[47]  R. Herbrecht,et al.  Clinical pharmacokinetics of voriconazole. , 2006, International journal of antimicrobial agents.

[48]  D. Andes,et al.  Voriconazole Therapeutic Drug Monitoring , 2006, Antimicrobial Agents and Chemotherapy.

[49]  N. Wood,et al.  Investigation of the Potential Relationships Between Plasma Voriconazole Concentrations and Visual Adverse Events or Liver Function Test Abnormalities , 2006, Journal of clinical pharmacology.

[50]  H. Derendorf,et al.  Pharmacokinetic/Pharmacodynamic Profile of Voriconazole , 2006, Clinical pharmacokinetics.

[51]  R. Jacobs,et al.  Intravenous Voriconazole Therapy in a Preterm Infant , 2005, Pharmacotherapy.

[52]  J. Mehta,et al.  Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients , 2005, Bone Marrow Transplantation.

[53]  B. Keevil,et al.  Validation of an Assay for Voriconazole in Serum Samples Using Liquid Chromatography-Tandem Mass Spectrometry , 2004, Therapeutic drug monitoring.

[54]  B. Keevil,et al.  Adverse reactions to voriconazole. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[55]  A. Agrawal,et al.  Voriconazole-Induced Musical Hallucinations , 2004, Infection.

[56]  W. Haefeli,et al.  Voriconazole-induced QT interval prolongation and ventricular tachycardia: a non-concentration-dependent adverse effect. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[57]  R. Herbrecht Voriconazole: therapeutic review of a new azole antifungal , 2004, Expert review of anti-infective therapy.

[58]  M. Karlsson,et al.  Pharmacokinetics and Safety of Intravenous Voriconazole in Children after Single- or Multiple-Dose Administration , 2004, Antimicrobial Agents and Chemotherapy.

[59]  Judy E. Kim,et al.  Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. , 2004, Archives of ophthalmology.

[60]  N. Wood,et al.  Effect of food on the pharmacokinetics of multiple-dose oral voriconazole. , 2003, British journal of clinical pharmacology.

[61]  N. Wood,et al.  Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration. , 2003, British journal of clinical pharmacology.

[62]  N. Wood,et al.  Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. , 2003, British journal of clinical pharmacology.

[63]  N. Wood,et al.  The pharmacokinetics and safety of intravenous voriconazole - a novel wide-spectrum antifungal agent. , 2003, British journal of clinical pharmacology.

[64]  N. Wood,et al.  Effect of omeprazole on the steady-state pharmacokinetics of voriconazole. , 2003, British journal of clinical pharmacology.

[65]  D. Andes,et al.  In Vivo Pharmacokinetics and Pharmacodynamics of a New Triazole, Voriconazole, in a Murine Candidiasis Model , 2003, Antimicrobial Agents and Chemotherapy.

[66]  S. Roffey,et al.  Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[67]  M. Rinaldi,et al.  Development and Validation of a High-Performance Liquid Chromatography Assay for Voriconazole , 2003, Antimicrobial Agents and Chemotherapy.

[68]  N. Wood,et al.  Safety of voriconazole and dose individualization. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[69]  D. Andes In Vivo Pharmacodynamics of Antifungal Drugs in Treatment of Candidiasis , 2003, Antimicrobial Agents and Chemotherapy.

[70]  C. A. Kauffman,et al.  Voriconazole: a new triazole antifungal agent. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[71]  B. Potoski,et al.  The safety of voriconazole. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[72]  W. Sponsel,et al.  Determination of voriconazole in aqueous humor by liquid chromatography-electrospray ionization-mass spectrometry. , 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[73]  N. Wood,et al.  Pharmacokinetics and Safety of Voriconazole following Intravenous- to Oral-Dose Escalation Regimens , 2002, Antimicrobial Agents and Chemotherapy.

[74]  L. Dupuis,et al.  Therapeutic Drug Monitoring of Lamotrigine , 2002, The Annals of Pharmacotherapy.

[75]  H. Lazarus,et al.  Safety and Pharmacokinetics of Oral Voriconazole in Patients at Risk of Fungal Infection: A Dose Escalation Study , 2002, Journal of clinical pharmacology.

[76]  E. Thiel,et al.  Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[77]  J. Perfect,et al.  Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children , 2002, The Pediatric infectious disease journal.

[78]  D. Denning,et al.  Muco‐cutaneous retinoid‐effects and facial erythema related to the novel triazole antifungal agent voriconazole , 2001, Clinical and experimental dermatology.

[79]  J. Lavandera,et al.  Optimization of the separation of a group of antifungals by capillary zone electrophoresis. , 2001, Journal of chromatography. A.

[80]  A. Bernard,et al.  Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  L. See,et al.  Clinical Correlates of Antifungal Macrodilution Susceptibility Test Results for Non-AIDS Patients with Severe CandidaInfections Treated with Fluconazole , 2000, Antimicrobial Agents and Chemotherapy.

[82]  J. Peacock,et al.  Pseudallescheria boydii brain abscess successfully treated with voriconazole and surgical drainage: case report and literature review of central nervous system pseudallescheriasis. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[83]  Russell E. Lewis,et al.  Evaluation of Voriconazole Pharmacodynamics Using Time-Kill Methodology , 2000, Antimicrobial Agents and Chemotherapy.

[84]  J. Rodríguez-Tudela,et al.  Meningitis caused by Pseudallescheria boydii treated with voriconazole. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[85]  M. Rinaldi,et al.  Comparison of High-Performance Liquid Chromatographic and Microbiological Methods for Determination of Voriconazole Levels in Plasma , 2000, Antimicrobial Agents and Chemotherapy.

[86]  P. E. Verweij,et al.  Voriconazole (Pfizer ltd). , 1999, IDrugs : the investigational drugs journal.

[87]  D. Andes,et al.  Characterization and Quantitation of the Pharmacodynamics of Fluconazole in a Neutropenic Murine Disseminated Candidiasis Infection Model , 1999, Antimicrobial Agents and Chemotherapy.

[88]  D. Stopher,et al.  A rapid HPLC assay for voriconazole in human plasma. , 1998, Journal of pharmaceutical and biomedical analysis.

[89]  Michael H. Miller,et al.  Pharmacodynamics of Fluconazole in a Murine Model of Systemic Candidiasis , 1998, Antimicrobial Agents and Chemotherapy.

[90]  M. H. Ensom,et al.  Clinical Pharmacokinetics in the 21st Century , 1998, Clinical pharmacokinetics.

[91]  E. Thiel,et al.  Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia , 1997, British journal of haematology.

[92]  D. Stopher,et al.  Determination of a new antifungal agent, voriconazole, by multidimensional high-performance liquid chromatography with direct plasma injection onto a size-exclusion column. , 1997, Journal of chromatography. B, Biomedical sciences and applications.

[93]  H. Yamazaki,et al.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.

[94]  J. M. Byers What Is a Therapeutic Range , 1980 .